CONMED’s exciting history began in 1970, when we were first established by Eugene Corasanti in Utica, New York as Consolidated Medical Equipment, Inc. The company’s first product was the disposable ECG monitoring electrode. The electrode market was booming as disposable products began to rapidly gain acceptance. This began our growth streak in the medical device industry and we have been expanding ever since.

Today, CONMED manufactures and markets thousands of products to providers across the healthcare continuum. We are a leader in Orthopedics, General Surgery, Gynecology, Gastroenterology, Laparoscopy, Cardiology and Critical Care markets. We continue to offer innovation and value added customer service across all of our product lines.

With multiple manufacturing and design facilities, over 3,500 employees, and worldwide distribution, CONMED strives to improve the quality of healthcare by designing, producing and marketing innovative, high-quality products.

1970

CONMED was founded by Eugene Corasanti.

1989

CONMED completed its first major acquisition with the purchase of Aspen Labs from Bristol Myers Squibb making the company a very strong competitor in the electrosurgery market.

1997

CONMED acquired Linvatec and became the #2 worldwide producer of arthroscopy products and Orthopaedic powered surgical instrument.

2004

CONMED acquired the majority of the Gastroenterology and Pulmonology business from C.R. Bard.

2011

Agreement with Musculoskeletal Transplant Foundation (MTF), the world’s largest tissue bank, which gives us exclusive worldwide marketing rights for their sports medicine allograft tissue.

2014

Curt Hartman was named President and CEO of CONMED and has been continuing to lead the company into the next chapter of growth, profitability and improved performance.

2016

CONMED acquired SurgiQuest, helping to grow our Advanced Surgical division and continuing to improve the standard of care for minimally invasive surgery.

2019

CONMED acquired Buffalo Filter, a leading surgical smoke evacuation and filter technology company.

2020

CONMED turns 50 and boasts over 3,500 employees across six continents, with a mission to enable healthcare providers around the world to deliver exceptional outcomes to patients through accessible solutions.
CONMED announces that it transferred the listing of its common stock to the New York Stock Exchange (NYSE) from NASDAQ Global Market.

Eliminator - Model PET - Balloon Dilators - Brochure